Fact CheckerSign in

NCT07132489Not yet recruiting

Validation of New Biomarkers for Predicting No-Reflow in STEMI Patients Undergoing Primary PCI

Validation of Novel Metabolic, Inflammatory, and Hepatic-Renal Biomarkers-HbA1c/C-peptide Ratio, Neutrophil/HDL Ratio, and ALBI Score-for Predicting the No-Reflow Phenomenon After Primary PCI in Patients With STEMI.

Source: ClinicalTrials.gov · Last updated 29 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

To evaluate the diagnostic value of the selected emerging biomarkers in predicting the no-reflow phenomenon among patients presenting with STEMI undergoing primary PCI. These biomarkers include: HbA1c/C-peptide ratio Albumin-bilirubin (ALBI) score. Neutrophil/HDL ratio

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
114 (estimated)
First submitted
11 Aug 2025
Start date
1 Sept 2025
Primary completion date
1 Sept 2028
Lead sponsor
Assiut University
NCT number
NCT07132489

What you commit to

  • Study type: Observational
  • Planned participants: 114
  • From 1 Sept 2025 to the primary completion date, 1 Sept 2028
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • History of previous MI, PCI, or CABG

Other illness

  • Known chronic inflammatory or autoimmune diseases
  • Advanced renal or hepatic failure
  • Active infection or malignancy at presentation

Other

  • Incomplete data or refusal to consent

Who the study is looking for

  • Age ≥ 18 years
  • Suitable for and undergoing timely primary PCI based on symptoms and clinical judgment
  • Provision of informed consent

Sex: All

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.